Quick Answer
Olema Pharmaceuticals, Inc. reported Total Assets of $533.43 million for the year ending 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +18.3% in Total Assets from 2024 to 2025.
- This data is from Olema Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $331.30 million | Q2 2021: $322.23 million | Q3 2021: $309.80 million | Q1 2022: $277.42 million | Q2 2022: $250.60 million | Q3 2022: $232.00 million | Q1 2023: $195.77 million | Q2 2023: $177.62 million | Q3 2023: $292.80 million | Q1 2024: $263.69 million | Q2 2024: $254.56 million | Q3 2024: $230.17 million | Q1 2025: $409.64 million | Q2 2025: $382.00 million | Q3 2025: $352.45 million.
- Over the full 6 years of available data (2020 to 2025), Olema Pharmaceuticals, Inc.'s Total Assets has grown by 55.6%.
- Historical annual values: Fiscal year 2025: $533.43 million | Fiscal year 2024: $450.98 million | Fiscal year 2023: $276.95 million | Fiscal year 2022: $215.65 million | Fiscal year 2021: $295.95 million | Fiscal year 2020: $342.72 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: